Shares of Mesoblast Ltd (MSB.AU) are soaring, with the stock rising 8.93% during the intraday trading session.
The significant price jump follows the company's announcement on Friday that its cell therapy Ryoncil booked quarterly net revenue of $36 million, a notable increase from $30.3 million in the previous quarter. This positive earnings update has fueled investor optimism, driving the stock to its highest level in several months.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.